{"id":9704,"date":"2026-04-07T15:14:31","date_gmt":"2026-04-07T13:14:31","guid":{"rendered":"https:\/\/hemerion.com\/press-releases\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/"},"modified":"2026-05-03T18:08:43","modified_gmt":"2026-05-03T16:08:43","slug":"patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor","status":"publish","type":"press-releases","link":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/","title":{"rendered":"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d"},"content":{"rendered":"\n

Villeneuve d\u2019Ascq, France & Boston, USA – April 7, 2026<\/strong><\/strong><\/strong><\/p>\n\n

Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d<\/h1>\n\n
T\u00e9l\u00e9charger le communiqu\u00e9 de presse<\/a><\/div>\n\n

Hemerion Therapeutics, healthtech fran\u00e7aise en phase clinique dans le traitement innovant des cancers du cerveau, annonce aujourd’hui l\u2019arriv\u00e9e de Patrick Tricoli, PharmD, MBA, au poste de \u201cStrategy & Corporate Development Senior Advisor\u201d.<\/strong>Install\u00e9 de longue date \u00e0 Boston, Patrick Tricoli est un manager de haut niveau sp\u00e9cialiste du secteur de la sant\u00e9 aux USA. Il a notamment dirig\u00e9 la filiale am\u00e9ricaine et le business development mondial de Nanobiotix et pilot\u00e9 la strat\u00e9gie partenariale de la R&D de Sanofi dans le monde. <\/strong>Patrick Tricoli apporte \u00e0 Hemerion sa parfaite connaissance du march\u00e9 am\u00e9ricain et une vista strat\u00e9gique servie par une longue exp\u00e9rience : deux atouts essentiels pour acc\u00e9l\u00e9rer son d\u00e9ploiement aux US et sceller de nouveaux partenariats strat\u00e9giques.<\/strong><\/p>\n\n

Manager de haut niveau et sp\u00e9cialiste du secteur de la sant\u00e9 aux USA, Patrick Tricoli a notamment dirig\u00e9 la filiale am\u00e9ricaine et le business development de Nanobiotix. Il a \u00e9t\u00e9 dans ce cadre l\u2019architecte du partenariat entre Nanobiotix et J&J, valoris\u00e9 \u00e0 plus de 2 milliards $. <\/p>\n\n

Longtemps \u00e0 la t\u00eate des partenariats de R&D internationaux de Sanofi, il conna\u00eet aussi tr\u00e8s bien les probl\u00e9matiques de d\u00e9veloppement des startups healthtech et biotech : il a accompagn\u00e9 au plus haut niveau plusieurs acteurs majeurs dont NanOlogy, Curadigm et Rest Therapeutics. <\/p>\n\n

Il est en outre Conseiller du Commerce Ext\u00e9rieur (CCE) pour la Nouvelle-Angleterre et dirige un groupe d’experts sur les flux d’investissement entre les \u00c9tats-Unis et la France dans les secteurs de la biotechnologie et de la sant\u00e9.<\/p>\n\n

Bas\u00e9 \u00e0 Boston, Patrick Tricoli aura pour mission de piloter le d\u00e9veloppement d’Hemerion sur le march\u00e9 am\u00e9ricain o\u00f9 la healthtech r\u00e9alise ses avanc\u00e9es cliniques les plus significatives et b\u00e9n\u00e9ficie du soutien de la FDA.<\/p>\n\n

Cinq ann\u00e9es apr\u00e8s le lancement de la healthtech, cette nomination t\u00e9moigne de la maturit\u00e9 de l\u2019\u00e9quipe d\u2019Hemerion et de sa volont\u00e9 d’ancrer durablement ses op\u00e9rations cliniques et commerciales sur le premier march\u00e9 mondial de la sant\u00e9.<\/p>\n\n

\n\n

\u00ab\u00a0L\u2019arriv\u00e9e de Patrick est un signal fort pour nos investisseurs et partenaires. Son track-record exceptionnel dans le d\u00e9ploiement des th\u00e9rapies de rupture aux USA est un atout majeur pour valoriser nos avanc\u00e9es cliniques et orchestrer une premi\u00e8re mise sur le march\u00e9 dans le traitement du cancer du cerveau le plus r\u00e9pandu. <\/em>\u00ab\u00a0<\/em><\/p>\n\n

\"Maximilien<\/figure>
\n

Maximilien Vermandel CEO, Hemerion Therapeutics<\/strong><\/p>\n<\/div><\/div>\n\n

\n\n

\u00ab\u00a0Tout au long de ma carri\u00e8re, j\u2019ai rarement vu une innovation aussi \u00e9l\u00e9gante et cliniquement convaincante que la solution th\u00e9rapeutique de Hemerion \u2014 r\u00e9unissant un m\u00e9dicament, la puissance de la physique, ainsi que l\u2019impact et la pr\u00e9cision de la chirurgie, qui demeure un pilier majeur de l\u2019oncologie. Cette combinaison introduit un nouveau concept dans le traitement du cancer, avec le potentiel d\u2019am\u00e9liorer significativement les r\u00e9sultats dans le glioblastome et d\u2019autres tumeurs solides.Mon ambition est d\u2019int\u00e9grer cette technologie dans la pratique clinique courante aux \u00c9tats\u2011Unis et d\u2019acc\u00e9l\u00e9rer son adoption mondiale, afin de garantir un acc\u00e8s rapide au march\u00e9 pour un b\u00e9n\u00e9fice patient imm\u00e9diat. Atteindre cette vision reposera sur des partenariats avec les meilleurs collaborateurs strat\u00e9giques afin de maximiser son impact \u00e0 l\u2019\u00e9chelle mondiale. <\/em><\/em>\u00ab\u00a0<\/em><\/p>\n\n

\"Patrick<\/figure>
\n

Patrick Tricoli Strategy & Corporate Development Senior Advisor, Hemerion Therapeutics<\/strong><\/p>\n<\/div><\/div>\n\n

<\/div>\n\n
\n\n
T\u00e9l\u00e9charger le communiqu\u00e9 de presse<\/a><\/div>\n","protected":false},"author":207845438,"template":"","class_list":["post-9704","press-releases","type-press-releases","status-publish","hentry"],"yoast_head":"\nPatrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d - Hemerion<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d - Hemerion\" \/>\n<meta property=\"og:description\" content=\"Villeneuve d\u2019Ascq, France & Boston, USA – April 7, 2026 Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d Hemerion Therapeutics, healthtech fran\u00e7aise en phase clinique dans le traitement innovant des cancers du cerveau, annonce aujourd’hui l\u2019arriv\u00e9e de Patrick Tricoli, PharmD, MBA, au poste de \u201cStrategy & Corporate Development Senior Advisor\u201d.Install\u00e9 ... Lire plus\" \/>\n<meta property=\"og:url\" content=\"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/\" \/>\n<meta property=\"og:site_name\" content=\"Hemerion\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-03T16:08:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/hemerion.com\/wp-content\/uploads\/maximilien-vermandel-1.jpg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@HemerionTx\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/\",\"name\":\"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d - Hemerion\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/hemerion.com\\\/wp-content\\\/uploads\\\/maximilien-vermandel-1.jpg\",\"datePublished\":\"2026-04-07T13:14:31+00:00\",\"dateModified\":\"2026-05-03T16:08:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/#primaryimage\",\"url\":\"https:\\\/\\\/hemerion.com\\\/wp-content\\\/uploads\\\/maximilien-vermandel-1.jpg\",\"contentUrl\":\"https:\\\/\\\/hemerion.com\\\/wp-content\\\/uploads\\\/maximilien-vermandel-1.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/communiques-de-presse\\\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\",\"name\":\"Hemerion\",\"description\":\"Advancing cancer therapies at the speed of light\",\"publisher\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#organization\",\"name\":\"Hemerion\",\"url\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-logo.png?fit=1581%2C460&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/hemerion.com\\\/wp-content\\\/uploads\\\/hemerion-logo.png?fit=1581%2C460&ssl=1\",\"width\":1581,\"height\":460,\"caption\":\"Hemerion\"},\"image\":{\"@id\":\"https:\\\/\\\/hemerion.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/HemerionTx\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/hemerion-therapeutics\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCWwcUj-aSdo32OYwN5vjf8Q\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d - Hemerion","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/","og_locale":"fr_FR","og_type":"article","og_title":"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d - Hemerion","og_description":"Villeneuve d\u2019Ascq, France & Boston, USA – April 7, 2026 Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d Hemerion Therapeutics, healthtech fran\u00e7aise en phase clinique dans le traitement innovant des cancers du cerveau, annonce aujourd’hui l\u2019arriv\u00e9e de Patrick Tricoli, PharmD, MBA, au poste de \u201cStrategy & Corporate Development Senior Advisor\u201d.Install\u00e9 ... Lire plus","og_url":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/","og_site_name":"Hemerion","article_modified_time":"2026-05-03T16:08:43+00:00","og_image":[{"url":"https:\/\/hemerion.com\/wp-content\/uploads\/maximilien-vermandel-1.jpg","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_site":"@HemerionTx","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/","url":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/","name":"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d - Hemerion","isPartOf":{"@id":"https:\/\/hemerion.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/#primaryimage"},"image":{"@id":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/#primaryimage"},"thumbnailUrl":"https:\/\/hemerion.com\/wp-content\/uploads\/maximilien-vermandel-1.jpg","datePublished":"2026-04-07T13:14:31+00:00","dateModified":"2026-05-03T16:08:43+00:00","breadcrumb":{"@id":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/#primaryimage","url":"https:\/\/hemerion.com\/wp-content\/uploads\/maximilien-vermandel-1.jpg","contentUrl":"https:\/\/hemerion.com\/wp-content\/uploads\/maximilien-vermandel-1.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/hemerion.com\/fr\/communiques-de-presse\/patrick-tricoli-rejoint-hemerion-en-tant-que-strategy-corporate-development-senior-advisor\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/hemerion.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Patrick Tricoli rejoint Hemerion en tant que \u201cStrategy & Corporate Development Senior Advisor\u201d"}]},{"@type":"WebSite","@id":"https:\/\/hemerion.com\/fr\/#website","url":"https:\/\/hemerion.com\/fr\/","name":"Hemerion","description":"Advancing cancer therapies at the speed of light","publisher":{"@id":"https:\/\/hemerion.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/hemerion.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/hemerion.com\/fr\/#organization","name":"Hemerion","url":"https:\/\/hemerion.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/hemerion.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-logo.png?fit=1581%2C460&ssl=1","contentUrl":"https:\/\/i0.wp.com\/hemerion.com\/wp-content\/uploads\/hemerion-logo.png?fit=1581%2C460&ssl=1","width":1581,"height":460,"caption":"Hemerion"},"image":{"@id":"https:\/\/hemerion.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/HemerionTx","https:\/\/www.linkedin.com\/company\/hemerion-therapeutics\/","https:\/\/www.youtube.com\/channel\/UCWwcUj-aSdo32OYwN5vjf8Q"]}]}},"jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/press-releases\/9704","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/press-releases"}],"about":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/types\/press-releases"}],"author":[{"embeddable":true,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/users\/207845438"}],"version-history":[{"count":6,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/press-releases\/9704\/revisions"}],"predecessor-version":[{"id":9738,"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/press-releases\/9704\/revisions\/9738"}],"wp:attachment":[{"href":"https:\/\/hemerion.com\/fr\/wp-json\/wp\/v2\/media?parent=9704"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}